NEW YORK (GenomeWeb News) – Definiens today said that it has raised €10 million ($12.9 million) in a private round of financing.

The Munich, Germany-based firm said that it would use the proceeds for commercial expansion of its current business and to develop and commercialize clinical digital pathology products. Its image analysis and data mining tools are used for quantitative digital pathology in life sciences research and for tissue-based diagnostic biomarker development.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.